KANAGAWA, Japan (PRWEB) May 20, 2020
Background and purpose of this round
Metcela Inc., established in 2016, is a clinical-stage biotechnology company focused on researching and developing potentially curative fibroblast-based therapies for chronic diseases with limited therapeutic options. The company’s mission is to provide these patients with an innovative and alternative treatment option.
Through basic research and various pre-clinical studies, Metcela has discovered that VCAM-1-positive cardiac fibroblasts (VCFs) were capable of stimulating proliferation of cardiomyocytes and improving cardiac function through formation of new lymphatic vessels, a process known as lymphangiogenesis.
Metcela’s first clinical pipeline is an autologous VCF therapy, which eliminates the needs for costly and debilitating immunosuppressive agents required for other allogeneic therapies, in order to achieve its maximal potential as a cell therapy. In addition, VCF product do not contain any types of stem cells nor require gene modification during its manufacturing; thus, there is essentially no concern regarding the risks for tumor formation or unexpected gene mutation.
With these innovative technological advantages, Metcela has been in a collaborative joint study with Japan Lifeline Co., Ltd. (JLL) and University of Tsukuba since 2018 to develop the cell therapy product MTC001, combining VCFs and a specialized catheter system for target delivery of the cells to the heart. Most recently, Metcela completed the construction of a cell processing facility in preparation for the launch of the first clinical trial of MTC001 in early 2021. The funds raised in this financing round will further strengthen the manufacturing and quality assurance of the products and accelerate the development of other pipelines.
About the newly appointed outside director, Kenji Yamada
Metcela also announces the appointment of a new outside director, Kenji Yamada. Mr.Yamada also serves as the director of Japan Lifeline Co., Ltd. and has worked in the business management sector for the past several years. Metcela and JLL are currently co-developing a new cell injection catheter, capable of delivering VCFs to precise targets in the heart. Mr.Yamada’s addition to the board will further solidify the relationship of the two companies and strategically position ourselves in the realm of cell therapy for heart failure, leading to accelerated development of MTC001.
About investors of this round
About Japan Lifeline Co., Ltd.
Japan Lifeline Co., Ltd. was founded in 1981 as a trading company specializing in medical devices in the cardiovascular field. Since then, the company has established its unique business model in which it has the trading company function that brings cutting-edge products from overseas manufacturers to Japan, and also the manufacturing function that develops and produces in-house products, reflecting needs of clinical practice. The company has business bases to cover all over Japan and close ties with physicians and medical institutions that are leading innovations in the cardiovascular field. Making use of such superior business resources, Japan Lifeline is pursuing initiatives to provide excellent medical devices to clinical settings.
About Sony Innovation Fund
Sony Innovation Fund is dedicated to engaging with promising early-stage companies. Beyond investment, our mission is to provide access to the broader Sony world and its global network and collaborate with startups to foster business creation in new and existing areas of interest to Sony, catalyze a talented and passionate team, develop innovative and scalable technology, and explore new and emerging ecosystems.
About Tsukuba Exceed Fund (“TX Fund”)
TX Fund was created by Joyo Bank and The Joyo Industrial Research Institute, Ltd. in August of 2019. The focus of investment is in deep tech startups, particularly in seed rounds, founded by Japan’s leading research institutions, particularly around the Tsukuba Science City and the University of Tsukuba, and other surrounding areas along the Tsukuba Express line. TX Fund supports the startups by investing and provides hands-on support by utilizing the external expert network of Joyo Bank. Metcela was one of the first startups to be invested from TX Fund.
About Heart Failure
Heart failure is a complex condition in which the ability of the heart to pump blood decreases due to various causes. Majority of currently available treatment options only prevents the progress of the symptoms and preserve quality of life, and thus, is unable to cure the irreversible ailment.
Metcela discovered VCAM-1-positive Cardiac Fibroblast (VCF), a specific type of fibroblast that re-establishes favorable microenvironment within the damaged heart tissues. VCF can easily be cultured and is known to induce lymphangiogenesis and enhance proliferation of cardiomyocytes to regenerate the damaged tissues of the heart. Metcela’s intellectual property is covered by several patents (JP6241893 and JP6618066).
Headquarter: Tsuruoka-shi, Yamagata
Research center: Life Innovation Center 3-25-22 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-0821
Co-CEOs: Takahiro Iwamiya, Kenichi Nogami
Foundation: March 2016